Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
Sponsor: Kaohsiung Medical University
Summary
1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection. 2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.
Official title: Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy in the First-line Anti-H. Pylori Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
390
Start Date
2023-11-28
Completion Date
2026-12-31
Last Updated
2026-01-15
Healthy Volunteers
No
Conditions
Interventions
vonoprazan, amoxicillin, tripotassium dicitrate bismuthate
bismuth-amoxicillin-vonoprazan triple therapy
vonoprazan, amoxicillin
vonoprazan-amoxicillin dual therapy
rabeprazole, amoxicillin, clarithromycin
proton pump inhibitor-based standard triple therapy
Locations (1)
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan